Anteris Technologies (ASX:AVR) nabs $20M funding package

CEO W. Paterson discusses the new funding package and upcoming FDA activities

Anteris set the stage in 2020 to prepare for DurAVR™ THV to be implanted in humans in 2021

""

Anteris presenting at the Switzer Small & Micro-Cap Conference

CEO Wayne Paterson provided a company overview and discussed the strategic direction of Anteris, followed by a brief Q&A session with investors. The event was hosted by Peter Switzer and attendees had the opportunity to hear from ASX-listed small & micro-cap companies across a range of different sectors.

Bioshares November 2020 Report

Positive Data from First Five Patients in 15 Patient Pilot Study

Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

CEO Wayne Paterson is interviewed by Proactive Investors

CEO Wayne Paterson is interviewed by 180 Markets

CEO Wayne Paterson is interviewed by 180 Markets

The New Daily Podcast by John Elder with Prof Leon Neethling & Wayne Paterson

Anteris an Australian company’s innovative bid to transform heart valve technology

DurAVR™ Key Opinion Leader Summary

DurAVR™ Key Opinion Leader Summary

TAVR Key Opinion Leader Symposium

Full Video & CEO Presentation Deck

Credit Suisse Research Note

U.S. Medical Supplies & Devices TAVR KOL Symposium: Insights on Durability and the Future of TAVR Credit Suisse Research Note

CEO Wayne Paterson is interviewed by Ausbiz

The $5 billion market for valves to treat aortic stenosis, the most common heart valve disease, has the potential to double by 2025. CEO of Anteris Technologies, Wayne Paterson, was live with us and says the key points of difference for the Anteris valve are the anti-calcification feature and unique design. This innovation avoids the need for open-heart surgery, reducing the amount of time it requires for a patient to recover.

Bioshares July 2020 Report

Anteris Technologies TAVR Advisory Board Signals High Level Interest